Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S is dated August 17, 2026. The report details the company's ongoing share repurchase programme, which is part of a broader capital allocation strategy. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries.
Key Financial Metrics and Capital Allocation
The filing focuses on treasury share transactions rather than operational financial performance metrics such as revenue or profit.
- Total Repurchase Programme: Up to DKK 15 billion over a 12-month period beginning February 4, 2026.
- Specific Programme (May 6, 2026): Up to DKK 11,200,000,010.45 for B shares between May 6, 2026, and February 1, 2027.
- Accumulated Repurchases (as of Aug 14, 2026): 28,884,179 B shares purchased since February 4, 2026.
- Total Value Repurchased (since Feb 4, 2026): DKK 8,081,660,819.
- Average Purchase Price (since Feb 4, 2026): DKK 279.80 per B share.
- Treasury Shares Held: 42,924,876 B shares (1.0% of total share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
Material Changes and Recent Activity
Between August 10, 2026, and August 14, 2026, the company executed five transactions under the May 2026 programme:
| Date | Shares Purchased | Avg. Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| Aug 10, 2026 | 200,000 | 303.97 | 60,794,002 |
| Aug 11, 2026 | 200,000 | 308.66 | 61,731,241 |
| Aug 12, 2026 | 200,000 | 298.62 | 59,723,538 |
| Aug 13, 2026 | 200,000 | 297.68 | 59,536,173 |
| Aug 14, 2026 | 200,000 | 299.04 | 59,807,956 |
Accumulated transactions under the May 2026 programme total 14,125,000 shares with a value of DKK 4,281,660,830.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the DKK 15 billion limit during the 12-month period starting February 4, 2026. The company maintains its purpose to defeat serious chronic diseases, leveraging its heritage in diabetes.
Risks and Contingencies: The filing does not disclose specific operational risks or contingencies. It notes that the repurchase programme is conducted in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the remaining capacity of the DKK 15 billion repurchase programme (approx. DKK 6.9 billion remaining as of Aug 14, 2026).
- Confirm the current market price of B shares relative to the recent average purchase price of DKK 279.80.
- Review the full list of transactions on the company website (novonordisk.com) for updates post-August 14, 2026.
- Check the latest Form 20-F or quarterly reports for operational revenue and profit data, as this 6-K does not contain them.